検索結果 - Ignacio Garrido‐Laguna

結果の絞り込み
  1. 1
    TIGIT: a novel immunotherapy target moving from bench to bedside

    TIGIT: a novel immunotherapy target moving from bench to bedside 著者: Benjamin L. Solomon, Ignacio Garrido‐Laguna

    出版事項 2018
    全文の入手
    Revisão
    お気に入りに追加
    保存先:
  2. 2
    Novel Therapeutic Targets in Non-small Cell Lung Cancer

    Novel Therapeutic Targets in Non-small Cell Lung Cancer 著者: Filip Janků, Ignacio Garrido‐Laguna, Luboš Petruželka, David J. Stewart, Razelle Kurzrock

    出版事項 2011
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  3. 3
    Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle

    Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle 著者: Snehal Gajiwala, Anna Torgeson, Ignacio Garrido‐Laguna, Conan G. Kinsey, Shane Lloyd

    出版事項 2018
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  4. 4
    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes

    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes 著者: Filip Janků, Hesham M. Amin, Dan Yang, Ignacio Garrido‐Laguna, Jonathan C. Trent, Razelle Kurzrock

    出版事項 2010
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  5. 5
    Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer

    Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer 著者: Anna Torgeson, Shane Lloyd, Dustin Boothe, Randa Tao, Jonathan Whisenant, Ignacio Garrido‐Laguna, George M. Cannon

    出版事項 2017
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  6. 6
    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer

    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer 著者: Michael J. Pishvaian, Ignacio Garrido‐Laguna, Stephen V. Liu, Pratik S. Multani, Edna Chow‐Maneval, Christian Rolfo

    出版事項 2018
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  7. 7
    <i>KRAS</i> Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma

    <i>KRAS</i> Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma 著者: Carter Norton, Matthew Shaw, Zachary Rubnitz, Jarrod Smith, Heloisa P. Soares, Christopher Nevala-Plagemann, Ignacio Garrido‐Laguna, Vaia Florou

    出版事項 2025
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  8. 8
    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center 著者: Ignacio Garrido‐Laguna, Filip Janků, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock

    出版事項 2011
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  9. 9
    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers 著者: Filip Janků, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido‐Laguna, Razelle Kurzrock

    出版事項 2011
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  10. 10
    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors 著者: Ignacio Garrido‐Laguna, David S. Hong, Filip Janků, Ly M. Nguyen, Gerald S. Falchook, Siqing Fu, J. J. Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock

    出版事項 2012
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  11. 11
    A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

    A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer 著者: Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Elizabeth De Oliveira, Belén Rubio‐Viqueira, Steven J. Strawn, Michael J. Wick, James Martell, David Sidransky

    出版事項 2011
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  12. 12
    A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

    A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors 著者: Niharika B. Mettu, Susanna V. Ulahannan, Johanna C. Bendell, Ignacio Garrido‐Laguna, John H. Strickler, Kathleen N. Moore, Robert Stagg, Ann M. Kapoun, Leonardo Faoro, Sunil Sharma

    出版事項 2021
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  13. 13
    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors 著者: Filip Janků, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Xuemei Wang, Rajyalakshmi Luthra, David S. Hong, Aung Naing, Gerald S. Falchook, John W. Moroney, Sarina A. Piha‐Paul, Jennifer J. Wheler, Stacy Moulder, Siqing Fu, Razelle Kurzrock

    出版事項 2011
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  14. 14
    PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations

    PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations 著者: Filip Janků, Jennifer J. Wheler, Shannon N. Westin, Stacy Moulder, Aung Naing, Apostolia M. Tsimberidou, Siqing Fu, Gerald S. Falchook, David S. Hong, Ignacio Garrido‐Laguna, Rajyalakshmi Luthra, J. Jack Lee, Karen H. Lu, Razelle Kurzrock

    出版事項 2012
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  15. 15
    Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

    Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer 著者: Maria Cristina Villarroel, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Ana De Jesus‐Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison P. Klein, Daniel A. Laheru, Ross C. Donehower, Manuel Hidalgo

    出版事項 2010
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  16. 16
    PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

    PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes 著者: Filip Janků, Jennifer J. Wheler, Aung Naing, Vanda M. Stepanek, Gerald S. Falchook, Siqing Fu, Ignacio Garrido‐Laguna, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Stacy Moulder, J. Jack Lee, Rajyalakshmi Luthra, David S. Hong, Razelle Kurzrock

    出版事項 2012
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  17. 17
    First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors

    First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors 著者: Ignacio Garrido‐Laguna, Ian E. Krop, Howard A. Burris, Erika Hamilton, Fadi Braiteh, Amy Weise, Maysa Abu‐Khalaf, Theresa L. Werner, Steven Pirie‐Shepherd, Christopher J. Zopf, Mani Lakshminarayanan, Jaymes Holland, Raffaele Baffa, David S. Hong

    出版事項 2019
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  18. 18
    Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

    Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors 著者: Anthony B. El-Khoueiry, James S. Clarke, Tobias Neff, T. Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido‐Laguna, Emiliano Calvo, Jordi Rodón, Ben Tran, Peter J. O’Dwyer, Adam Cuker, Albiruni R. Abdul Razak

    出版事項 2023
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  19. 19
    Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC

    Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC 著者: Vaia Florou, Andrew Elliott, Matthew H. Bailey, David Stone, Kajsa E. Affolter, Heloisa P. Soares, Christopher Nevala-Plagemann, Courtney L. Scaife, Phillip Walker, W. Michael Korn, Emil Lou, Rachna T. Shroff, Peter J. Hosein, Ignacio Garrido‐Laguna

    出版事項 2023
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  20. 20
    652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

    652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (... 著者: Kathryn C. Arbour, Salman Rafi Punekar, Ignacio Garrido‐Laguna, David S. Hong, Brian M. Wolpin, Meredith S. Pelster, M. Barve, Alexander Starodub, D. Sommerhalder, Sam S. Chang, Y. Zhang, Zeena Salman, X. Wang, Corinne E. Gustafson, Alexander I. Spira

    出版事項 2023
    全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: